Our experts have written, co-written, and provided insights into hundreds of publications.
Soini E, et al. Level and factors impacting the patient dissatisfaction in the primary care visits based on the cross-section measurement – A prospective Finnish study. Value in Health 2013;16(7):A336.
Asseburg C, Riekkinen O, Karjalainen J, Kröger H, Soini E. Current and future strategy for osteoporosis screening and diagnostics: Cost-effectiveness of FRAX with or without pulse-echo ultrasound measurement of bone mineral density and DXA on demand. Value in Health 2013;16:A564-5.
Asseburg C, Valgarðsson S, Soini E. Cost-effectiveness of sequences of biologic treatments for moderate-to-severe psoriasis in Finland. Value in Health 2013;16(7):A507-8.
Martikainen J, et al. Early psychosocial intervention to delay institutionalization of patients with Alzheimer’s disease – a randomised controlled trial. 28th International Conference of Alzheimer’s Disease International, 18-20 April 2013, Taipei, Taiwan.
Soini E, et al. Level and factors impacting the patient dissatisfaction in the primary care visits based on the cross-section measurement – A prospective Finnish study. 18th Nordic Congress of General Practice, Tampere, Aug 8, 2013.
Asseburg C, Soini E, et al. Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-TNF treatments in an outcomes-based risk-sharing scheme in Finland. Ann Rheum Dis 2013;72(Suppl3):A434.
Asseburg C, Riekkinen O, Karjalainen JP, Kröger H, Soini E. Cost-effectiveness of pulse-echo ultrasound measurement of bone mineral density as a tool for osteoporosis screening and diagnostics. European Congress on Osteoporosis and Osteoarthritis, Rome, Italy, 17-20 April 2013.
Soini E, Hallinen T, et al. Cost-utility of first-line adalimumab and tocilizumab monotherapies in rheumatoid arthritis based on head-to-head data. Value in Health 2013;16(7):A566.
Lehto SM, Sahlman J, Soini E, et al. The association between anxiety and the degree of illness in mild obstructive sleep apnoea. Clin Respir J 2013;7(2):197-203.
Ryynänen OP, Nousiainen P, Soini E, et al. Efficacy of a multicomponent support programme for the caregivers of disabled persons: A randomized controlled study. Z Gerontol Geriatr 2013;46(5):449-55.
Martikainen J, Kautiainen H, Väätäinen S, et al. Effectiveness of the early psychosocial intervention on institutionalization of patients with mild Alzheimer’s disease and caregivers’ quality of life. Value in Health 2013;16(7):A618-9.
Väätäinen S, Hongisto K, Hallikainen I, Välimäki T, Martikainen J, et al. Wellbeing, life satisfaction and progression in Alzheimer’s disease. Value in Health 2013;16(7):A267.
Soini E, et al. International Normalized Ratio (INR) monitoring and percent Time in Therapeutic INR Range (TTR) have impact on patient’s quality of life? Application of Beta regressions in a prospective 3 months setting. Value in Health 2013;16(7):A535.
Väätäinen S, Tuomilehto H, Saramies J, Tuomilehto J, Uusitalo H, Hussi E, Keinänen-Kiukaanniemi S, Martikainen J. The health-related quality-of-life impact of nocturnal awakenings in the middle-aged and older Finnish population. Qual Life Res 2013;22:2737-48.
Hallikainen M, et al. Cholesterol Metabolism and Weight Reduction in Subjects with Mild Obstructive Sleep Apnoea: A Randomised, Controlled Study. Cholesterol 2013;769457. Collaborators: Soini E, Martikainen J.
Willis M, Asseburg C, He J. Validation of Economic and Health Outcomes simulation model of Type 2 Diabetes Mellitus (ECHO-T2DM). J Med Econ 2013;16(8):1007-21.
Theidel U, Asseburg C, et al. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol 2013;102(6):447-58.
Ryynänen OP, Soini, E, et al. Bayesian predictors of very poor health related quality of life and mortality in patients with COPD. BMC Med Inform Decis Mak 2013;13:34.
Rasvan laadun muutoksen ja suolan vähentämisen taloudellinen merkitys. Tie Sydämeen 2012;(1):4-5. Lähteenä luento. Mar 7, 2012: Martikainen J.
Soini E. ESiOR auttaa toiminnan kriittisessä tarkastelussa. Kunnallissuomi 2012;(1):22.
Tuomilehto H, et al. Weight Reduction and Increased Physical Activity to Prevent the Progression of Obstructive Sleep Apnea: A 4-Year Observational Postintervention Follow-up of a Randomized Clinical Trial. JAMA Intern Med 2013;173(10):929-30. Collaborators: Soini E, Martikainen J.
Soini E, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus 2013;2:531.
Asseburg C. Estimating Weibull parameters from Kaplan-Meier curves. ISBA 2012, Kyoto.
Hallinen T, Linnosmaa I, Tuovinen M, Soini E. Vaihtoehtoiskustannukset ja kustannusvaikuttavuus tuotantoteknologian muuttuessa: esimerkkinä eteisvärinän antikoagulaatiohoito. In: Klavus J (ed.) Terveystaloustiede 2012. Helsinki: THL, 69-73.
Soini E. Kustannusvaikuttavuustiedon tuottamisen rooli, haasteet ja mahdollisuudet nyt ja tulevaisuudessa. KWRC Seminar. Oct 22, 2012.
Soini E. Follikulaarisen lymfooman sekventiaalisen hoidon kustannusvaikuttavuus. BESTPRACTICE ONKOLOGIA / HEMATOLOGIA Lääketieteen asiantuntijoiden ammattilehti 2012;1(2):28-31.
Ainutlaatuinen kokonaisuus – Lääketutkimuksen kehittäjät. Lääketeollisuus ry:n ilmoitusliite Kauppalehti Nov 21, 2012. Tulevaisuuden lääkkeet, p. 3. Yksi haastatelluista: Soini, E.
Fimean suositus lääkkeiden hoidollisen ja taloudellisen arvon arvioinnista (Fimea recommendation for the assessment of the therapeutic and economic value of pharmaceuticals). Fimea kehittää, arvioi ja informoi -julkaisusarja 2/2012 (Serial Publication Fimea Develops, Assesses and Informs 2/2012). Projektiryhmän jäsen / project team member: Martikainen, J.
Asseburg C, Soini E, et al. Cost-effectiveness and budget impact of certolizumab pegol against a mix of treatments in an outcomes-based risk-sharing scheme in Finland. Value Health 2012;15(7):A454.
Martikainen J, Soini E, et al. Economic impact of 13-valent pneumococcal conjugate vaccine (PCV13) in persons over 50 years of age with underlying chronic medical conditions in Finland. Value Health 2012;15(7):A388-9.